you, Thank Steve.
Steve As months. over development progress important we've past noted, clinical made with few the pipeline our
a standard unprecedented Our has lead data, drug demonstrated candidate, dangerous Based on seen effect comparable previously akathisia trial, be precursor in most of side the in considered depression. lurasidone, these with to by of antidepressant reductions significantly suicidal this many in perhaps a suicidality to the the reducing which while Indeed, side our published peer-reviewed NRX-XXX NRX-XXX is drugs, what NRX-XXX, suicide. to current in data has and literature. class of delivered care, akathisia, efficacy been is bipolar have effect STABIL-B
this second So the we is this time result. found
in with ever demonstrated in to seen no of along consistently XX% of the antidepressant prior studies literature akathisia. application risk has filing the strong XX% these are Together, in reduction new with at support FDA with is for a of patients who take a Akathisia akathisia. depression drugs, and provide lurasidone people others drug the who class for bipolar
novel warning FDA effects. placed today's effects, label of combined of precedent FDA antidepressants. The current comparable potential antidepressants It well reduced is with risks a existing aware that antidepressant the antidepressants on and requires of suicide all currently be have approval with that for associated is the side
to of they've have unambiguous most welcome key the akathisia that depression, with that drug they identifying the drugs we of spoken this the as us been opinion lethal effect bipolar side far, drugs. effect. side new Those are a in reduces would So are lurasidone told leaders potentially class troubling and have the whom used treat that
leader and for later opinion this discussion key depression Bipolar Hospital. details. at invited and bipolar Harvard meeting look with the study's month Head Psychopharmacology the to principal Society American conference, Miami, these at of We Nierenberg, of host data been Clinical Andrew present Professor please We've of Mass the to Research together and akathisia that in investigator aim at a General
drug drug The product this second we're presented is for in that's new France, government is further and for additional by a of data, is literature, from Columbia the from but form Therefore, required and well the our data support data supported are planning established, we've of always of been of for in University University ketamine medical HTX-XXX, application. the IV detail efficacy approval. the which to data important application suicidal it's licensed FDA to the FDA. Harvard including never the treatment The format depression. dose-ranging patient-level this The to findings
ketamine of we've and skin anticipate It's ketamine designated and will to not announced support generic Last intravenous month, We be patentable to old is can commercial the product a dates the highly back the HTX-XXX. used we for ulcers. but it subcutaneous that Hope formulation be treatment. PH causes of acidic, neutral Now, It of this formulation a to for infusions, that Korean limitation War. market we Therapeutics. the that form bring hurts
While it's cumbersome IV the failed ketamine patients, Intranasal hand, offers administration setting. numerous ketamine properties. has other on for benefits to to the clinical anti-suicidal in demonstrate
We has a of more ketamine are far with efficacy. aim that equal with augment to it but going administration convenient form IV to start
an matter demonstrate of Though with vitally in in is country, of exceptional really an all our important each therapy. million the Americans we've this electroconvulsive degree for ketamine. CDC treatment epidemic. national plan is treated presented a when approximately depressed is hours By states year. active This patients X.X The where at studies in take suicidally efficacy commit approved only the to suicide a measures, suicidality
anti-suicidal intranasal soon for possible. is ketamine plan to million, market The properties. $XXX current to market a doesn't as We have bring as product and that's this that life-saving already product
expect our be We larger. much to market
To seek the for Therapeutics continue network and national company existing building a the our product in distribute public team, term listing our launching value we that our to on of shareholders shares a XXXX. to shareholders, to the We're partners for of in intend and near build goal early exchange. with NRx actively to out Hope
To known operators, it's combat augment ketamine, a the previously development digital a Advanced I in the IV developing reduce efficacy was and DARPA, and a Agency, to whose Research many funded Navy extend therapeutic. in by to of therapeutic the Projects still stress planning digital in as U.S. product, participated companion Defense for special forces use. we're development of
our I'm Officer, completed former has duty, leading Chief be company. his will this announce that Strategy just Dennis tour project delighted our of McBride, who of to Today, behalf on
in of Defense most the from hearing Dennis years which more tours includes weeks. appointed X our the website. program is duty coming His XX in officer in You'll a as of of be office recently, an Undersecretary biography, the Navy, on DARPA and
of digital and be help expected and stay label our our expect of to enhance it to product technologic We'll patients ketamine build we that part build this digital to market exclusivity. the effect The will therapeutic and to track. on addition Ultimately, extend suicidal further on these learnings will our advances is therapeutics FDA exclusivity.
ability the suicidal insurers ketamine therapy, for treatment approach FDA the which people of Obtaining need many to enhance our approval to depression. cover cost will so of
clinics key treatment aim to problem patients the the We reimbursement to that bring this impediments with to to able and discussions indicated of life. need. have to the Our one that hope lack is date to get of being they solve
revenues by the FDA a as can't under United on anticipate you for made. gain in drug manufacturing to month, X-month States. with already with In ketamine standards. pharmacy other in approval license. drug drug distribute identified you In Pharmaceuticals. the Nephron first you to endpoint We commercial able Nephron, being our a manufacture Ketamine for FDA near publicly And XXXB are haven't we is to drug, order future. a to have partnership shortage This approval together reporting the we're in a get stability in words, a
conducted XXX-patient of with chronic await at see University the you We're results component a as NRX-XXX. those pain eager We being sponsored results. of key study as Defense of in Northwestern Department are the D-cycloserine, to currently
plan the have now the that Northwestern Northwestern at colleagues the has and advised us Board, IRB, locked, the approved Institutional analysis the clearance for Our and data Review is statistical analysis. giving database
highly beyond have would today's Advil available the class option. opioid NRX-XXX patients. Because Tylenol, and those to in efficacy, offer class a addictive, may treatment between you choice in are of lack drugs but treatment nonaddictive a drugs chronic not NRX-XXX much pain highly of for but the that currently effective that be middle. that treatments the of offers a possibility may the world,
opened tract we urinary January, in for and NRX-XXX complicated know, in infection IND an pyelonephritis. you As
the but are Now the life as in the began reason it different D-cycloserine antibiotic. from its bacteria an fact, affects reasons drug completely this affects brain,
fact, respected that urinary on from pathogens. in the So these lists worst organization, was The NRX-XXX or of motivated of status, to highly qualified IND qualify mandated Charles QIDP a the pathogens disease study resistant can fast that against effect a the on status. Labs, priority dangerous FDA congressionally research data a are antibacterial contract QIDP, demonstrated us with and that sponsored designations. significant called along what's track infectious River And based grant and data pathogens for review we recently product you
weeks demonstrating called as not important critically C. Several we ago, complicated reported the is Well, disrupt that bacteria known well other for difficile. damage the intestinal in that's does normal to microbiome, the the the they're all antibiotics result microbiome. intestine in UTI infection reason known data and NRX-XXX an
Some people call diff. C. it
at best, diarrhea. of horrible C. Now several causes diff weeks intractable
cause antibiotic However, appeal. is the age does have C Therefore, to market likely who is not that an diff over complicated of in were UTI for lethal of those XX% diff considerable infected. XX C.
hallucinations, represent an devastating our early-stage schizophrenia at FundaMental Paris for may their effect degrees. schizophrenia are treat world's has we're first varying population the and to diminish knows the working with The its debilitating disease-modifying this of of Everybody Finally, of used may medicines the patients symptoms, X% the partners disease. the families. especially opportunity drug to on that Foundation schizophrenia. in lifelong
providing a a disease quarter. with there's reverse this that the the of in first may disease complete presentation schizophrenia end potential anticipate -- patients. first be by our However, on We never the that is for -- what been to has potentially curative modifying medicine some investors the drug
financials. bring our hardest Narido, As have a you multibillion hope Rich? potential. I'll day with to We our dollar ask quarter this to to development and every bring we CFO, plan work clinical review the to reality to can now robust plan life. see, first Rich
